Larimar Therapeutics, Inc. (LRMR) — SEC Filings
Larimar Therapeutics, Inc. (LRMR) — 43 SEC filings. Latest: 8-K (Dec 17, 2025). Includes 22 8-K, 6 10-Q, 5 SC 13G/A.
View Larimar Therapeutics, Inc. on SEC EDGAR
Overview
Larimar Therapeutics, Inc. (LRMR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 5, 2025: Larimar Therapeutics, Inc. (LRMR) reported a significant increase in net loss for the three and nine months ended September 30, 2025, primarily driven by a substantial rise in research and development (R&D) expenses. The net loss for the three months ended September 30, 2025, was **$47.7 million**,
Sentiment Summary
Across 43 filings, the sentiment breakdown is: 1 bearish, 40 neutral, 2 mixed. The dominant filing sentiment for Larimar Therapeutics, Inc. is neutral.
Filing Type Overview
Larimar Therapeutics, Inc. (LRMR) has filed 22 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 5 SC 13G/A, 3 SC 13G, 3 SC 13D/A with the SEC between Feb 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (43)
Risk Profile
Risk Assessment: Of LRMR's 33 recent filings, 2 were flagged as high-risk, 13 as medium-risk, and 18 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$103.2M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $90.1M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Brian R. Markison
- Dr. Paul L. Williams
- Dr. Donald L. Staiger
- Michael Celano
- Joseph Truitt
- Carole S. Ben-Maimon, M.D.
- James E. Flynn
Industry Context
Larimar Therapeutics operates in the biotechnology sector, specifically focusing on rare diseases like Friedreich's Ataxia. This niche requires significant R&D investment and faces a complex regulatory landscape. The competitive environment for rare disease therapies is growing, with companies often relying on expedited pathways and strong clinical data to gain market access.
Top Tags
8-K (10) · financials (7) · Biotechnology (4) · corporate-filing (4) · pharmaceutical (4) · 10-Q (4) · corporate-update (3) · sec-filing (3) · Larimar Therapeutics (3) · institutional-investor (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (Q3 2025) | $47.7M | Increased from $15.5M in Q3 2024, indicating higher operational costs. |
| Net Loss (9M 2025) | $103.2M | More than doubled from $51.8M in 9M 2024, reflecting accelerated R&D. |
| R&D Expenses (9M 2025) | $94.9M | Increased from $46.5M in 9M 2024, showing significant investment in nomlabofusp. |
| Cash & Cash Equivalents (Sep 30, 2025) | $90.1M | Increased from $33.2M at Dec 31, 2024, bolstered by equity financing. |
| Common Shares Outstanding (Nov 3, 2025) | 85,590,392 | Increased from 63,815,065 at Dec 31, 2024, due to stock issuance. |
| Proceeds from Common Stock Issuance (9M 2025) | $65.3M | Key financing activity to support operations and R&D. |
| SEC File Number | 001-36510 | Identifies the company's filing with the SEC |
| IRS Employer Identification No. | 20-3857670 | Company's tax identification number |
| Net Loss | $55.46M | Increased 52.8% for six months ended June 30, 2025, from $36.28M in 2024. |
| Research and Development Expenses | $49.92M | Increased 53.0% for six months ended June 30, 2025, from $32.62M in 2024. |
| Cash and Cash Equivalents | $20.59M | Decreased from $33.22M at December 31, 2024, indicating significant cash burn. |
| Short-term Marketable Securities | $117.94M | Decreased from $150.24M at December 31, 2024, contributing to reduced liquidity. |
| Accumulated Deficit | $324.62M | Increased from $269.16M at December 31, 2024, reflecting ongoing losses. |
| Net Loss Increase | 52.8% | Percentage increase in net loss for the six months ended June 30, 2025, compared to 2024. |
| R&D Expense Increase | 53.0% | Percentage increase in R&D expenses for the six months ended June 30, 2025, compared to 2024. |
Forward-Looking Statements
- {"claim":"Larimar Therapeutics will release detailed financial results for the period ending December 31, 2023, shortly after this 8-K filing.","entity":"Larimar Therapeutics, Inc.","targetDate":"2024-03-31","confidence":"high"}
- {"claim":"The 'Other Events' section of this 8-K will disclose a significant corporate development, such as a new clinical trial update or partnership.","entity":"Larimar Therapeutics, Inc.","targetDate":"2024-02-12","confidence":"medium"}
Frequently Asked Questions
What are the latest SEC filings for Larimar Therapeutics, Inc. (LRMR)?
Larimar Therapeutics, Inc. has 43 recent SEC filings from Feb 2024 to Dec 2025, including 22 8-K, 6 10-Q, 5 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of LRMR filings?
Across 43 filings, the sentiment breakdown is: 1 bearish, 40 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Larimar Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Larimar Therapeutics, Inc. (LRMR) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Larimar Therapeutics, Inc.?
Key financial highlights from Larimar Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for LRMR?
The investment thesis for LRMR includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Larimar Therapeutics, Inc.?
Key executives identified across Larimar Therapeutics, Inc.'s filings include Brian R. Markison, Dr. Paul L. Williams, Dr. Donald L. Staiger, Michael Celano, Joseph Truitt and 2 others.
What are the main risk factors for Larimar Therapeutics, Inc. stock?
Of LRMR's 33 assessed filings, 2 were flagged high-risk, 13 medium-risk, and 18 low-risk.
What are recent predictions and forward guidance from Larimar Therapeutics, Inc.?
Recent forward-looking statements from Larimar Therapeutics, Inc. include guidance on {"claim":"Larimar Therapeutics will release detailed financial results for the period ending December 31, 2023, shortly and 1 other predictions.